Kidney Cancer Drugs Market Size, Share & Trends Report

Kidney Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (Targeted Therapy, Immunotherapy), By Pharmacologic Class, By Country, And Segment Forecasts, 2016 - 2022

  • Published Date: Jun, 2018
  • Base Year for Estimate: 2016
  • Report ID: GVR-2-68038-514-4
  • Format: Electronic (PDF)
  • Historical Data:
  • Number of Pages: 99

Table of Contents

Chapter 1 Research Methodology
                     1.1. Information procurement
                     1.2. Information or Data Analysis
                         1.2.1 Market Formulation & Validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
                     3.1. Disease Primer
                     3.2. Epidemiology
Chapter 4 Global Market Overview
                     4.1 Market by Therapeutic Class
                     4.2 Market Size and Forecast 2016 - 2022
                     4.3 Market Share Distribution, by Company 2016 - 2022
                     4.4 Sales Performance, by Pharmacologic Class
                     4.5 Market Dynamics and Brand Strategies
                     4.6 Patent Expiry Analysis
                     4.7 Kidney Cancer Drugs Market: Drivers and Restraints
                         4.7.1 Drivers
                         4.7.2 Challenges
                     4.8 M&A, Deal Landscape (2013 - 2017 YTD)
                         4.8.1 Mergers & Acquisitions
                         4.8.2 Deals Landscape
                     4.9 Evolution of Biosimilars
                     4.10 Emerging Markets
                     4.11 Reimbursement Scenario
                     4.12 Kidney Cancer Sector SWOT
Chapter 5 Pipeline Intelligence
                     5.1. Pipeline Landscape
                         5.1.1 Leading Drugs in Development
                         5.1.2 Key R&D Trends
                     5.2 Pipeline Landscape
                         5.2.1 Late Stage Pipeline and Sales Forecast
                         5.2.2 Profiles of Disruptive Drugs
                     5.3 Global Pipeline Forecast
Chapter 6 Company Profiles
                     6.1 Pfizer
                         6.1.1 Company Overview
                         6.1.2 Current Product Portfolio
                         6.1.3 Product Sales Forecast Through 2022
                         6.1.4 Strategic Initiatives
                             6.1.4.1 Key Company News Flow
                             6.1.4.2 Catalysts & Events Calendar
                         6.1.5 Pipeline Analysis & Overview
                         6.1.6 SWOT
                     6.2 Novartis
                         6.2.1 Company Overview
                         6.2.2 Current Product Portfolio
                         6.2.3 Product Forecast Sales Through 2022
                         6.2.4 Strategic Initiatives
                             6.2.4.1 Key Company News Flow
                         6.2.5 Pipeline Analysis & Overview
                         6.2.6 SWOT
                     6.3 Bayer
                         6.3.1 Company Overview
                         6.3.2 Current Product Portfolio
                         6.3.3 Product Forecast Sales Through 2022
                         6.3.4 Strategic Initiatives
                             6.3.4.1 Key Company News Flow
                         6.3.5 Pipeline Analysis & Overview
                         6.3.6 SWOT
                     6.4 Genentech
                         6.4.1 Company Overview
                         6.4.2 Current Product Portfolio
                         6.4.3 Product Forecast Sales Through 2022
                         6.4.4 Strategic Initiatives
                             6.4.4.1 Key Company News Flow
                             6.4.4.2 Catalysts & Events Calendar
                         6.4.5 Pipeline Analysis & Overview
                         6.4.6 SWOT
                     6.5 Bristol-Myers Squibb
                         6.5.1 Company Overview
                         6.5.2 Current Product Portfolio
                         6.5.3 Product Forecast Sales Through 2022
                         6.5.4 Strategic Initiatives
                             6.5.4.1 Key Company News Flow
                             6.5.4.2 Catalysts & Events Calendar
                         6.5.5 Pipeline Analysis & Overview
                         6.5.6 SWOT
                     6.6 Exelixis
                         6.6.1 Company Overview
                         6.6.2 Current Product Portfolio
                         6.6.3 Product Forecast Sales Through 2022
                         6.6.4 Strategic Initiatives
                             6.6.4.1 Key Company News Flow
                             6.6.4.2 Catalysts & Events Calendar
                         6.6.5 Pipeline Analysis & Overview
                         6.6.6 SWOT
                     6.7 Eisai
                         6.7.1 Company Overview
                         6.7.2 Current Product Portfolio
                         6.7.3 Product Forecast Sales Through 2022
                         6.7.4 Strategic Initiatives
                             6.7.4.1 Key Company News Flow
                         6.7.5 Pipeline Analysis & Overview
                         6.7.6 SWOT
                     6.8 Prometheus Labs
                         6.8.1 Company Overview
                         6.8.2 Current Product Portfolio
                         6.8.3 Product Forecast Sales Through 2022
                         6.8.4 Strategic Initiatives
                             6.8.4.1 Key Company News Flow
                         6.8.5 SWOT
Chapter 7 Market Outlook
                     7.1 What the Future Holds
                     7.2 The Winners and Losers
                         7.2.1 Winners
                         7.2.2 Losers
                     7.3 Emerging Companies & Technology Platforms
                     7.4 The Road Ahead


List of Tables

TABLE 1 Incidence Rate per 100,000 in Seven Major Markets
TABLE 2 Incidence Rate per 100,000 in Forecast, Spain
TABLE 3 Marketed Drugs for Kidney Cancer
TABLE 4 Marketed Drugs for Kidney Cancer
TABLE 5 Sales Performance by Therapeutic Class, 2016 - 22
TABLE 6 Sales Performance by Market, in USD million, 2016 - 22
TABLE 7 Sales Performance by Market, by Pharmacologic Class, 2016 - 22
TABLE 8 Sales Performance by Pharmacologic Class, 2016 - 22
TABLE 9 U.S. Patents for Current Kidney Cancer Drugs
TABLE 10 Avastin (bevacizumab) Biosimilars Across Various Indications
TABLE 11 R&D Pipeline Overview
TABLE 12 Late Stage Pipeline
TABLE 13 Bavencio
TABLE 14 Tecentriq
TABLE 15 Fotivda
TABLE 16 Epacadostat
TABLE 17 Rocapuldencel-T
TABLE 18 Pipeline Forecast
TABLE 19 Pfizer Sales Forecast, 2016 - 2022
TABLE 20 Pfizer Pipeline
TABLE 21 Novartis Sales Forecast, 2016 - 2022
TABLE 22 Bayer Sales Forecast, 2016 - 2022
TABLE 23 Bayer Pipeline
TABLE 24 Genentech (Roche) Sales Forecast, 2016 - 2022
TABLE 25 Genentech (Roche) Pipeline
TABLE 26 Bristol-Myers Squibb Sales Forecast, 2016 - 2022
TABLE 27 Bristol-Myers Squibb Pipeline
TABLE 28 Exelixis Sales Forecast, 2016 - 2022
TABLE 29 Exelixis Pipeline
TABLE 30 Eisai Sales Forecast, 2016 - 2022
TABLE 31 Prometheus Labs Sales Forecast, 2016 - 2022


List of Figures

FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Race and Gender Specific Prevalence of RCC in the U.S.
FIG. 8 Gender Specific Incidence Rate per 100,000 in the U.K. (1993 - 2014)
FIG. 9 Kidney Cancer Drugs Market Share, by Therapeutic Class, 2016 - 22
FIG. 10 Regional Market Size, 2016 - 2022
FIG. 11 Market Shares Distribution, 2016 - 2022
FIG. 12 Sales by Pharmacologic Class, 2016 - 2022
FIG. 13 Kidney Cancer SWOT
FIG. 14 Pfizer SWOT Analysis
FIG. 15 Novartis SWOT Analysis
FIG. 16 Bayer SWOT Analysis
FIG. 17 Genentech SWOT Analysis
FIG. 18 Bristol-Myers Squibb SWOT Analysis
FIG. 19 Exelixis SWOT Analysis
FIG. 20 Eisai SWOT Analysis
FIG. 21 Prometheus Labs SWOT Analysis

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.